Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Open Forum Infect Dis ; 10(2): ofad003, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-36846608

RESUMO

Mpox has recently re-emerged as a global entity of concern. We report one of the first pediatric cases in the United States and provide updated recommendations relevant to infection control and prevention measures of those in close contact with mpox.

3.
JAMA ; 328(13): 1348-1350, 2022 10 04.
Artigo em Inglês | MEDLINE | ID: mdl-35994281

RESUMO

This case series describes the clinical resolution of systemic symptoms and lesions, along with any adverse events, in patients with monkeypox infection who were treated with tecovirimat on a compassionate use basis.


Assuntos
Antivirais , Benzamidas , Ensaios de Uso Compassivo , Mpox , Ftalimidas , Antivirais/uso terapêutico , Benzamidas/uso terapêutico , Humanos , Isoindóis/uso terapêutico , Mpox/tratamento farmacológico , Ftalimidas/uso terapêutico
4.
Genet Med ; 23(11): 2105-2113, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34257420

RESUMO

PURPOSE: To address demands for timely germline information to guide treatments, we evaluated experiences of patients with ovarian, pancreatic, and prostate cancer with a mainstreaming genetic testing model wherein multigene panel testing was ordered by oncologists with standardized pretest patient education, and genetic counselors delivered results and post-test genetic counseling via telephone. METHODS: Among 1,203 eligible patients, we conducted a prospective single-arm study to examine patient uptake and acceptability (via self-report surveys at baseline and three weeks and three months following result return) of this mainstreaming model. RESULTS: Only 10% of eligible patients declined participation. Among 1,054 tested participants, 10% had pathogenic variants (PV), 16% had variants of uncertain significance (VUS), and 74% had no variant identified (NV). Participants reported high initial acceptability, including high satisfaction with their testing decision. Variability over time in several outcomes existed for participants with PV or NV: those with NV experienced a temporary increase in depression (pTime < 0.001; pTime2 < 0.001), and those with PV experienced a small increase in genetic testing distress (p = 0.03). Findings suggested that result type, sex, and cancer type were also associated with outcomes including clinical depression and uncertainty. CONCLUSION: This mainstreaming model may offer a feasible approach for extending access to germline genetic information.


Assuntos
Predisposição Genética para Doença , Neoplasias da Próstata , Aconselhamento Genético , Testes Genéticos , Humanos , Masculino , Estudos Prospectivos , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/genética
5.
Can J Urol ; 26(5 Suppl 2): 57-59, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31629436

RESUMO

Demand for cancer genetic counseling has grown rapidly in recent years as germline genomic information has integrated into cancer care. There are currently an insufficient number of genetic counselors (GC) to address genetic testing need through traditional pre- and post-test counseling. Alternative genetic counseling frameworks, discussed here, are under study to increase access to genetic testing while optimizing the skillsets of existent master's-trained GCs.


Assuntos
Aconselhamento Genético , Testes Genéticos , Neoplasias da Próstata/diagnóstico , Atenção à Saúde/métodos , Humanos , Masculino , Neoplasias da Próstata/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...